[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360690-105":59,"doc-detail-360690-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-and-immune-landscape-of-recurrent-andor-distant-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-an-eortcimmucan-project","Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project","","Recurrent and/or metastatic squamous cell carcinoma of the head and neck is a heterogeneous disease with poor prognosis and an underexplored molecular and immune landscape. An EORTC/IMMUCAN study used RNA sequencing, whole-exome sequencing, and multiplex immunofluorescence on 253 fresh tumor biopsies to characterize tumor microenvironment and profiles. Treatment-line number emerged as a key driver of immune decline, while specific pathway enrichments and genomic alterations defined clinical and anatomic subgroups. Epithelial–mesenchymal transition signatures linked to poor survival, whereas lymphocyte infiltration with tertiary lymphoid structures associated with improved outcomes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-and-immune-landscape-of-recurrent-andor-distant-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-an-eortcimmucan-project/360690/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-and-immune-landscape-of-recurrent-andor-distant-metastatic-squamous-cell-carcinoma-of-the-head-and-neck-an-eortcimmucan-project/360690.png","ImageObject",300,407,{"name":92,"@type":93},"Kurz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main aim of this study on R/M SCCHN?","Question",{"text":112,"@type":113},"To provide an in-depth view of the tumor microenvironment and molecular profile of recurrent and/or metastatic squamous cell carcinoma of the head and neck, including how clinical factors shape molecular and immune features.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which methods and sample type were used?",{"text":117,"@type":113},"The study analyzed 253 fresh tumor biopsies using RNA sequencing, whole-exome sequencing, and multiplex immunofluorescence.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical factor most affected the immune microenvironment?",{"text":121,"@type":113},"The number of treatment lines, with significant declines in T cells and B cells as the number of R/M treatment lines increased.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360690,1790149733,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project  \nAthna van der Elst1,2,3, Daniel Herrero-Saboya3,4,5, Lucas Michon3,6,7, Marie Morfouace3,8,9, Robin Liechti3,10,11, Preethi Devanand3,12,13,14, Daniel Schulz3,15,16, Maya Persoons3,8,  \nSylvie Rusakiewicz3,12,13,14, Nils Eling3,15,16, Paul-Antoine Nicolas3,17, Marie-Sophie Robert3,8, Stephanie Tissot3,12,13,14, Sophie Dglise3,15,16, Bruno Palau Fernandez3,15,16, Bernd Bodenmiller3,15,16, Henoch S. Hong3,18, Rachel Galot1,2, Paolo Bossi19,20, Julio Oliveira21, Marc Pracht22, Caroline Even23, Pierre Saintigny3,6,7,24, Cline Lefebvre3,5, Loredana Martignetti3,4, and Jean-Pascal Machiels1,2,3  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: Recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) is a heterogeneous clinical entity with a poor prognosis. The molecular and immune landscape of R/M SCCHN is underexplored. To offer a comprehensive view of the tumor microenvironment and molecular profile of R/M SCCHN, we performed an in-depth molecular and immune characterization, evaluating the impact of human papillomavirus (HPV) status, tobacco and alcohol history, primary tumor site, relapse pattern, and treatment history at the genomic, transcriptomic, and immune levels.\u003Cbr>Experimental Design: We analyzed 253 R/M SCCHN fresh tumor biopsies from the IMMUcan project using RNA sequencing (RNA-seq), whole-exome sequencing, and multiplex immunofluorescence (mIF) .\u003Cbr>Results: The primary clinical factor affecting the immune microenvironment was the number of treatment lines, with significant declines in T cells and B cells observed via mIF and RNAseq as the number of R/M treatment lines progressed. IL6, IL13,\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | IL15, and NRF2 pathways were enriched in HPV-negative R/M SCCHN compared with HPV-positive tumors, whereas no immune differences were detected between these two clinical groups. Specific genomic alterations were observed in laryngeal cancer (DDR2, FOXP1, KLF5, and ROBO2), whereas nonsmokers/nondrinkers exhibited alterations in SPEN, PBRM1, and CYLD. 11q13.3 amplification was linked to HPV-negative metastatic tumors and hypopharyngeal cancer. HPV-negative SCCHN with locoregional recurrence showed elevated EGFR and CXCL12 pathway activity. Partial epithelial–mesenchymal transition transcriptomic\u003Cbr>signatures correlated with poor survival, whereas lymphocyte infiltration, especially in the context of tertiary lymphoid structures, was associated with improved survival.\u003Cbr>Conclusions: Our study highlights key molecular and immune differences across R/M SCCHN subgroups, identifies potential biomarkers, and suggests biological rationales for tailored therapeutic strategies. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nSquamous cell carcin","cbCainjUenfpOpR1","https://ap.wps.com/l/cbCainjUenfpOpR1","pdf",5194244,16,"English","# Introduction\n## Purpose\n## Experimental Design\n## Results\n## Conclusions","[{\"question\":\"What was the main aim of this study on R/M SCCHN?\",\"answer\":\"To provide an in-depth view of the tumor microenvironment and molecular profile of recurrent and/or metastatic squamous cell carcinoma of the head and neck, including how clinical factors shape molecular and immune features.\"},{\"question\":\"Which methods and sample type were used?\",\"answer\":\"The study analyzed 253 fresh tumor biopsies using RNA sequencing, whole-exome sequencing, and multiplex immunofluorescence.\"},{\"question\":\"What clinical factor most affected the immune microenvironment?\",\"answer\":\"The number of treatment lines, with significant declines in T cells and B cells as the number of R/M treatment lines increased.\"}]","Molecular and Immune Landscape of Recurrent and/or Distant Metastatic Squamous Cell Carcinoma of the Head and Neck: An EORTC/IMMUCAN Project | PDF",1790141174,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2d5ed2d4e8ca855287aa49a764e24e42.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/61e337b5fac1694c042cdb1e0747487e.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7da92fbd59ab591a1e5231b86aeda29.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55eb9ed83414b75c095481e6cdab0325.webp",980,1311]